Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
Summary
The Offering will be made pursuant to the filing of a prospectus supplement (the Supplement) to the Companys short form base shelf prospectus dated June 27, 2023 (the Prospectus).In connection with the Offering, Numinus has secured a lead order from Integrated V.C., a venture fund partnering with value-aligned companies and entrepreneurs that are transforming the health and well-being of communities around the globe, and additional participation by the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization specializing in research and education so people can benefit from the careful use of psychedelics and marijuana for mental health, well-being, and connection.As we continue to build out our comprehensive offering to address the pressing challenges of mental health in our communities, this financing provides important resources to help us achieve our goals, said Payton Nyquvest, Numinus Founder and CEO. For more than half a century, therapists have expressed a desire to have the opportunity for their own psychedelic experiences as part of their training to feel better prepared to use these medicines to treat their patients. The Numinus model including psychedelic research and clinic care is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.Learn more at and follow us on , , , and .This press release contains forward-looking statements within the meaning of applicable securities laws. These risks and uncertainties include, but are not limited to, dependence on obtaining regulatory approvals and the possibility that the Offering does not close when expected, or at all, because conditions to closing are not satisfied on a timely basis, or because the underwriters exercise their termination rights; ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; the Companys need for additional financing and the effects of financial market conditions and other factors on the availability of capital; and other risk factors set forth in the Supplement, the Prospectus and our annual information form dated November 29, 2023, each available on SEDAR+ at www.sedarplus.ca.